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Abstract
Immune cells promote the initial metastatic dissemination of carcinoma cells from primary 
tumors. In contrast to their well-studied functions in the initial stages of metastasis, the specific 
roles of immunocytes in facilitating progression through the critical later steps of the invasion-
metastasis cascade remain poorly understood. Here we define novel functions of neutrophils in 
promoting intraluminal survival and extravasation at sites of metastatic dissemination. We show 
that CD11b+/Ly6G+ neutrophils enhance metastasis formation via two distinct mechanisms. First, 
neutrophils inhibit natural killer cell function, which leads to a significant increase in the 
intraluminal survival time of tumor cells. Thereafter, neutrophils operate to facilitate extravasation 
of tumor cells through the secretion of IL-1β and matrix metalloproteinases. These results identify 
neutrophils as key regulators of intraluminal survival and extravasation through their crosstalk 
with host cells and disseminating carcinoma cells.
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 INTRODUCTION
The metastatic spread of tumor cells to distant sites is estimated to be responsible for at least 
90% of cancer-related mortality, but the mechanisms leading to these secondary growths are 
incompletely understood. Evidence accumulated in recent years demonstrates that the 
invasive and metastatic traits of cancer cells are often governed by complex interactions 
between cancer cells and surrounding stromal cells of host origin. This crosstalk extends 
across multiple stages of the invasion-metastasis cascade - the sequence of events that 
commences with locally invasive primary tumor cells, proceeds through their intravasation, 
transport and survival in the circulation, extravasation into the parenchyma of distant tissues, 
formation of micrometastases, and finally their colonization of these tissues, yielding 
macroscopic metastases (1). While the tumor-promoting effects of immune cells acting at 
the primary tumor site have been studied extensively (2-6), relatively little is known about 
how circulating immune cells affect the dynamics of the later phases of the invasion-
metastasis cascade.
Among the various immune cell populations of the host, studies of the contributions of 
neutrophils to cancer biology have been overshadowed by examinations of other cell types, 
most notably macrophages. Furthermore, the role of neutrophils in cancer has been a subject 
of controversy, as both tumor-promoting and -suppressing effects have been reported (7-15). 
Neutrophils have been implicated in cancer pathogenesis because of their ability to secrete 
cytokines, such as IL-1β, which is known to activate endothelial cells (16), and proteases, 
such as matrix metalloproteinases (MMPs), which can cleave components of the 
extracellular matrix (ECM) as well as cell-surface adhesion molecules (17). In addition, 
MMPs can liberate growth factors that are bound in an inactive state either to the ECM or to 
the plasma membrane, thereby making these factors readily available to cancer cells (18, 
19). Acting in these ways, MMPs have been shown to contribute to the local invasion and 
intravasation steps of the invasion-metastasis cascade (20-24).
Independent of the localized interactions between cancer cells and neutrophils, neutrophils 
can play a role in the systemic response to tumorigenesis. For example the systemic effects 
of tumors on host physiology, including neutrophilia, are often observed in murine models 
of cancer as well as in cancer patients (3, 5, 25-28). Moreover, elevated levels of circulating 
neutrophils represent a marker of poor prognosis in cancer patients (29, 30).
In the present study, we demonstrate that the systemic effects initiated by neoplastic cells 
residing in the primary tumor profoundly impact their vascular intraluminal survival and 
extravasation at distant metastatic sites. More specifically, our results demonstrate that 
neutrophils, mobilized by the primary tumors, have the ability to prevent NK cell-mediated 
clearance of tumor cells from initial sites of dissemination while concurrently facilitating the 
extravasation of tumor cells into the lung parenchyma.
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 RESULTS
 Tumor metastasis is facilitated by neutrophils
In order to study systemic mechanisms that facilitate tumor progression, we employed an 
established in vivo experimental system using the previously described murine mammary 
carcinoma 4T1 cells (31, 32). When injected subcutaneously (s.c.) into syngeneic BALB/c 
hosts, 4T1 cells form vigorously growing primary tumors and are able to complete all steps 
of the metastatic cascade, resulting in the formation of large numbers of visible metastatic 
nodules in the lungs (31). We confirmed earlier reports using the 4T1 tumor model (12-14, 
33), and observed a 100-fold elevation in the number of circulating white blood cells 
(WBCs) in 4T1 tumor-bearing mice (hereafter termed 4T1 mice; 4 weeks post-implantation) 
relative to normal control hosts; neutrophils accounted largely for this expansion of the 
WBC compartment (Fig.1A). Of note, implantation of 4T1 tumors either orthotopically or 
subcutaneously yielded similar effects in terms of neutrophilia as well as splenomegaly 
(Supplementary Fig. 1A). Accordingly, we proceeded with subcutaneous implantation of 
4T1 cells,since this method eliminates the significant immune effects that result from the far 
more invasive orthotopic surgery and post-surgical wound healing.
ELISA analysis demonstrated that cultured 4T1 cells secreted high levels of G-CSF 
(1.14± 0.35 ng/ml /106 cells), a cytokine that has been shown to cause the expansion and 
mobilization of neutrophils (12). Furthermore, given that the expression of the G-CSF 
receptor was undetectable in this tumor cell line (Supplementary Fig. 1B), it was unlikely 
that the secreted G-CSF acted in an autocrine manner. Hence, the 4T1 tumor model and its 
associated neutrophilia provided the necessary platform to study the role of neutrophils in 
cancer progression.
We also noted a 10-fold increase in spleen weight of 4T1 mice, (Fig. 1B) and wished to 
determine whether this splenomegaly contributed in any way to the metastatic ability of the 
4T1 cells, since the spleen can serve as an important reservoir of myeloid cells such as 
neutrophils (34). To test this notion we removed the spleens of BALB/c mice prior to 
implanting 4T1 tumor cells s.c.. We chose splenectomy because post-surgical recovery is 
rapid and there are few systemic side-effects on host physiology. In splenectomized mice 
relative to non-splenectomized 4T1 mice, we observed a 50% reduction in the total number 
of circulating WBCs, which was paralleled by a similar reduction in the number of 
neutrophils at the time the experiments were terminated (4-5 weeks post- 4T1 cell 
implantation; Supplementary Fig. 1C). While there was no reduction in the weights of 
primary tumors in splenectomized mice (Fig. 1C), splenectomy prior to subcutaneous 
injection of 4T1 tumor cells led to a 56% reduction in the number of pulmonary metastases 
formed relative to those in the control, sham-operated mice (Fig. 1D, 1E).
We wished to further verify that the efficient metastasis of 4T1 tumor cells depended in 
significant part on systemic physiologic effects. To address this possibility, we asked 
whether implantation of 4T1 tumors would affect the spontaneous metastasis of D2A1 
murine mammary carcinoma cells implanted subcutaneously on the contralateral flank of a 
syngeneic host BALB/c mouse. When implanted on their own, D2A1 primary tumors rarely 
spawn pulmonary metastases (35). However, D2A1 cells are able to form macroscopic 
Spiegel et al. Page 3
Cancer Discov. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
metastases in the lung when injected in large numbers intravenously (36). (Of note, the 
number of neutrophils in D2A1 tumors was 5-fold lower than that found in 4T1 tumors - 
1,634±318/gram of tumor and 8,127±1762/gram of tumor, respectively.)
While no significant change in D2A1 primary tumor weight was noted in response to 
contralateral implantation of 4T1 cells (Fig. 1F), a 22-fold increase in the number of D2A1-
derived lung metastases was observed relative to D2A1 tumors implanted contralaterally to 
control Matrigel implants (Fig. 1G). These results indicated that 4T1 cells could create a 
systemic environment that enabled metastasis of otherwise-non-metastatic or weakly 
metastatic carcinoma cells. We mention in passing that the contralateral implantation of 
D2A1 cells did not affect the number of 4T1 metastatic lesions. Importantly, splenectomy 
substantially reduced the ability of 4T1 tumors to induce the metastasis of contralaterally 
implanted D2A1 tumors, as evidenced by a 67% decrease in D2A1 pulmonary metastases 
(Fig. 1H). Hence, optimal expression of the systemic effects wrought by 4T1 cells depended 
on an intact spleen, which ostensibly served as a reservoir for myeloid cells mediating these 
effects.
We proceeded to express G-CSF in D2A1 cells, which do not on their own ordinarily 
express this cytokine. G-CSF overexpression in D2A1 cells (secreted levels were 
comparable and even slightly higher than 4T1 cells; Supplementary Fig 1D), was able to 
phenocopy the systemic neutrophilia provoked by 4T1 tumors (Fig. 1I) and yielded a 54-fold 
increase of D2A1 metastases formed in the lungs (Fig. 1J). Collectively, these experiments 
demonstrated that the G-CSF-driven expansion of neutrophils is both necessary and 
sufficient for this response.
While the mechanism of the systemic potentiation of metastasis was still undefined at this 
point, its effects on D2A1 cells were transient and reversible. Thus, when we isolated D2A1 
tumor cells that had successfully metastasized to the lungs of contralaterally implanted 4T1 
mice and re-injected these cells into naive mice, the previously metastasized D2A1 cells 
were no more able, on a per cell basis, to metastasize than parental cells that had not 
experienced the systemic environment present in a 4T1-bearing host (data not shown).
These results pointed to an important role for neutrophils in driving metastasis. To further 
explore the contributions of neutrophils to this process, we asked whether normal, 
physiologic levels of neutrophils, rather than the dramatic neutrophilia observed in 4T1-
bearing hosts, might also function to promote tumor metastasis. To address this question, we 
depleted neutrophils in non-tumor bearing mice by injecting the 1A8 monoclonal antibody, 
which depletes specifically Ly6G+ neutrophils but not granulocyte receptor-1 (Gr-1)+ 
monocytes (37). This depletion of neutrophils prior to intravenous injection (a route that 
allows them to form metastatic lesions as cited earlier) of D2A1 cells led to a 56% decrease 
in metastases in the lungs of these animals (Fig. 1K). Thus, even normal, physiologic levels 
of circulating neutrophils could indeed promote metastasis, and enhancing these levels could 
serve as a useful experimental tool to better understand the role of immune cells in tumor 
metastasis. Furthermore, the results of this experiment suggested that neutrophils might 
primarily impact post-intravasation processes, an issue that we address in more detail below.
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 Neutrophils facilitate intermediate steps of the invasion-metastasis cascade
Responding to the above-described results, we attempted to delineate the specific step(s) of 
the invasion-metastasis cascade that were affected by the neutrophils. To address whether 
mobilized neutrophils might infiltrate the primary tumor and affect cells within these 
growths, D2A1 cells were co-mixed with splenocytes from 4T1-bearing mice and co-
injected subcutaneously into BALB/c mice. No metastatic D2A1 nodules were observed in 
these mice, indicating that direct heterotypic interactions between the splenocytes and the 
tumor cells within the primary tumor were unlikely to be responsible for the observed 
increased metastasis (data not shown).
We next tested whether the systemic environment in 4T1 mice affected the ability of D2A1 
tumor cells to intravasate. When D2A1 cells were implanted contralaterally to 4T1 tumors, 
only a marginal (2-fold) increase was observed in the number of circulating D2A1 tumor 
cells 4-5 weeks post implantation of the primary tumors (relative to control mice in which 
D2A1 cells had been implanted contralaterally to Matrigel plugs; Supplementary Fig. 2A). 
These results suggested that the >20-fold increase in D2A1 metastasis triggered by distant 
4T1 primary tumors (Fig. 1H) was not likely to result from differences in the ability of 
D2A1 primary tumor cells to intravasate at increased rates in the presence of the distant 4T1 
tumors.
Collectively, the above experiments suggested that the metastasis-promoting role of 
neutrophils act on the post-intravasation steps of the invasion-metastasis cascade. To directly 
test this notion, we asked whether the systemic environment of a 4T1-bearing host would 
promote the metastasis of intravenously injected D2A1 cells that have bypassed the early 
steps of invasion and intravasation because of their route of introduction into mice. We 
injected a relatively small number of D2A1 cells (2×104), as this size of inoculum more 
closely mimics conditions of spontaneous metastasis. Under these conditions we found that 
mice bearing already-established subcutaneous 4T1 tumors experienced a 12-fold increase in 
the number of D2A1 lung foci relative to naïve mice.
We extended these analyses to both MDA-MB-231 human breast cancer cells and B16-F10 
mouse melanoma cells (both injected into immune-deficient NOD/SCID mice) and observed 
similarly strong metastasis promotion in 4T1-bearing mice (Fig. 2A) upon i.v. injection of 2 
× 104 cells. These results provided direct evidence that the previously observed systemic 
effects of primary 4T1 tumors could be ascribed largely, if not entirely, to facilitation of the 
later (i.e., post-intravasation) steps of the invasion-metastasis cascade.
We reasoned that the observed metastasis-promoting effects of established 4T1 primary 
tumors on intravenously injected tumor cells could result from two alternative mechanisms: 
i) tumor cells disseminated by the 4T1 primary tumors reached the lungs earlier than the 
D2A1 cells and persisted in this tissue, thereby creating a favorable pulmonary 
microenvironment for subsequent metastasis formation by D2A1 cells; or ii) the G-CSF 
released by 4T1 cells induced mobilization of neutrophils that facilitate the metastasis of 
D2A1 cells.
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To address the first possibility, we injected 2×104 4T1 cells intravenously, one day before 
injection of D2A1 cells. However, no increase in the number of D2A1 metastases formed 
was detected under these conditions (Supplementary Fig. 2B), eliminating direct interactions 
between 4T1 and D2A1 cells in the lungs as a cause for the increased metastasis of D2A1 
cells in 4T1-bearing mice
Wishing to critically test the second hypothesized mechanism, we determined whether the 
splenocytes induced by 4T1 primary tumors sufficed, on their own, to increase the 
metastasis of D2A1 cells. We therefore performed adoptive transfer of splenocytes isolated 
from 4T1-bearing mice into naïve, non-tumor-bearing mice. One hour after introduction of 
these splenocytes, D2A1 cells were injected intravenously into these mice. As depicted in 
Figure 2B, adoptive transfer of splenocytes prior to intravenous injection of D2A1 cells led 
to a 6.6-fold increase in eventual metastasis formation by D2A1 cells.
Taken together, these results indicated that the observed increase in metastasis elicited by 
4T1 tumors was mediated primarily, and possibly entirely, by 4T1-mobilized neutrophils 
that could, on their own, drive enhanced metastasis formation. Conversely, a significant 
contribution of disseminated 4T1 carcinoma cells that had arrived previously in the lungs 
and created a “niche” for subsequently arriving D2A1 cells was ruled out.
Localization of the effects of 4T1 tumors to the later steps of the invasion-metastasis cascade 
allowed us to further resolve the effects of G-CSF. Thus, treating mice with 5 daily 
injections of G-CSF prior to the intravenous injection of D2A1 cells resulted in a 48-fold 
increase in the number of D2A1 lung metastases (Fig. 2C). Hence, subcutaneously 
introduced G-CSF could essentially phenocopy the effects of 4T1 primary tumors.
Wishing to ensure that G-CSF acts via the mobilization of neutrophils rather than by 
alternative mechanisms, we repeated the above experiment using the adoptive transfer of 
splenocytes from tumor-free mice that had been treated with G-CSF (5 daily injections). The 
number of D2A1 pulmonary metastases was 9-fold higher in recipients of splenocytes from 
these G-CSF-treated mice relative to injection of the same number of splenocytes from 
control PBS-treated mice (Fig. 2D). Hence, these effects in enhancing metastasis formation 
operated after the entrance of the immune cells into the general circulation and once again 
appeared to be confined to the later stages of the invasion-metastasis cascade. Moreover, this 
effect could be achieved by cells that accumulated in large numbers in the spleens following 
systemic G-CSF treatment.
We addressed post-extravasation effects of 4T1-induced splenocytes by examining the 
effects of circulating immune cells on colonization, i.e., the outgrowth of micrometastases in 
the lung parenchyma into macroscopic deposits. Thus, we injected D2A1 cells intravenously 
into naïve mice and allowed them 48 hours to extravasate , thereby enabling us to focus 
solely on post-extravasation events. We note that D2A1 cells extravasate in less than 48 
hours after entering the circulation (38)). When we thereafter injected splenocytes from 4T1-
bearing mice into these mice, we observed no increase in the number of lung macro-
metastases formed by the previously extravasated D2A1 cells relative to control mice that 
had not been treated with adoptive transfer of splenocytes (Supplementary Fig. 2C). These 
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observations, when taken together, indicated that the G-CSF-induced neutrophils acted to 
foster metastasis after intravasation but before post-extravasation colonization.
 Neutrophils increase accumulation of cancer cells in the lungs
We attempted to delineate with even more precision the specific post-intravasation steps of 
metastasis that were facilitated by neutrophils. When comparing survival of D2A1 tumor 
cells in control and 4T1-bearing hosts, we found that 24 hours after i.v. injection of D2A1 
cells, the number of these cells that were present in the lungs of 4T1 primary tumor-bearing 
mice was greatly increased (50 fold) compared to the D2A1 cells detected in naïve hosts 
(Fig. 2E). We further tested whether primary tumors derived from either D2A1 or B16-F10 
cells, engineered in both cases to express ectopic G-CSF, would be able to promote retention 
of D2A1 cells in the lungs after i.v. injection. As mentioned above (Supplementary Fig. 1D) 
for D2A1 cells, this forced expression of G-CSF in B16-F10 cells resulted in secreted levels 
of this cytokine that were comparable to those secreted by 4T1 cells (Supplementary Fig. 
2D). The number of D2A1 cells retained in the lungs was increased 20-fold in mice bearing 
D2A1-G-CSF primary tumors and 11-fold in mice bearing B16-F10-G-CSF primary tumors 
relative to corresponding control tumors that did not secrete this cytokine (Fig. 2F). Hence, 
in both cases, the forced expression of G-CSF resulted in greatly increased retention of 
disseminated cells within the lungs.
We proceeded to assess a specific role for neutrophils in mediating tumor cell retention in 
the lung. In fact, the spleens of 4T1-mice are populated by heterogenous populations of 
cells. In order to test for the specific involvement of neutrophils, we conducted adoptive 
transfer experiments in which Ly6G+-enriched neutrophils were injected into naïve, non-
tumor-bearing mice. One hour after introduction of the neutrophils, D2A1 cells were 
injected intravenously into these mice. This led to a 3.5–fold increase in the number of 
D2A1 cells retained in the lung (Fig. 2G).
We further verified that tumor cell retention in the lungs was mediated specifically by 
neutrophils by treating 4T1 tumor-bearing mice with the neutrophil-depleting 1A8 antibody. 
This resulted in a 54% reduction in the number of D2A1 cells found in the lungs of 4T1 
mice 24 hours after i.v. injection, relative to untreated or IgG-treated controls (Fig. 2H). 
Furthermore, physiological levels of neutrophils present in naïve, non-tumor-bearing mice 
were also important in facilitating retention of intravenously-injected tumor cells, as 
evidenced by the fact that depletion of these neutrophils (using anti-Ly6G antibodies) 
resulted 24 hours later in a 58% reduction (relative to untreated or IgG- treated controls) in 
the number of i.v. injected D2A1 cells found in the lungs of mice (Fig. 2I). Hence, even the 
normally present circulating neutrophils are intrinsically capable of facilitating metastasis by 
increasing the accumulation of tumor cells in the lungs within the short time period after 
introduction of the tumor cells into the venous circulation.
 Neutrophils inhibit NK-mediated clearance of tumor cells
The observed increased accumulation of carcinoma cells in the lungs was compatible, in 
principle, with three alternative neutrophil-mediated mechanisms: more efficient physical 
trapping of intravasated carcinoma cells in the lung microvessels, enhanced intraluminal 
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survival of intravasated cells, or elevated extravasation of these cells. Accordingly, we 
explored the trapping of D2A1 cells in the lung capillary beds using in vivo bioluminescent 
measurements conducted 10 min after i.v. injection; in this instance, we found no significant 
differences in the numbers of D2A1 cells found in the lungs of naïve mice or 4T1-bearing 
mice. This indicated that initial physical trapping of cells in pulmonary microvessels was not 
affected by the presence of splenocytes (Fig. 3A, 3B).
A significant difference in the number of D2A1 cells in the lungs was apparent, however, 
soon after this initial trapping. Thus, 70% of D2A1 cells injected into naïve mice had been 
cleared from the lungs within 4 hours after intravenous injection (Fig. 3A, 3B). In contrast, 
in mice bearing 4T1 primary tumors, only 20% of the D2A1 cells were cleared from the 
lungs of 4T1 mice by this time. These results suggested that the systemic changes in mice 
bearing 4T1 primary tumors acted to reduce the otherwise-rapid attrition of D2A1 cells 
initially trapped in the lungs (Fig. 3B).
We hypothesized that the neutrophils might protect cancer cells from rapid intraluminal 
clearance from pulmonary microvessels by inhibiting the natural killer (NK) cells, which are 
normally responsible for this function (39, 40). By depleting NK cells in BALB/c mice using 
the anti-asialo-GM-1 antibody (41), we determined that NK cell do, in fact, clear D2A1 cells 
from the circulation. Thus, ablation of NK cells prior to injection of D2A1 cells resulted in a 
5.5-fold increase in the number of D2A1 cells found in the lung 4 hours after i.v. injection of 
these tumor cells (Fig. 3C).
Similarly, depletion of NK cells in a C57BL/6 background using the strain-specific antibody 
NK1.1 resulted in a 7-fold increase in the number of B16-F10 melanoma cells found in the 
lung 4 hours after intravenous injection of the tumor cells (Supplementary Fig. 3). These 
observations indicated that NK cells play a major role in preventing tumor cell accumulation 
in the lungs, ostensibly by reducing the intraluminal survival time of the tumor cells. 
Importantly, when NK cells were depleted 24 hours after injection of D2A1 cells -- a time 
when tumor cells have either extravasated or been cleared from the vasculature -- no 
increase in lung metastases was observed (Fig. 3D), indicating that NK cells acted while the 
cancer cells still resided within the lumina of microvessels, not thereafter.
We wished to further validate that the increased survival of intraluminal D2A1 cells 
promoted by neutrophils in 4T1-bearing hosts was due to protection of these cells from NK-
mediated clearance and not by some other neutrophil-induced, NK-independent mechanism. 
To distinguish between these possibilities, we depleted NK cells from 4T1 mice (by treating 
with anti-asialo-GM1) prior to intravenous injection of D2A1 cells. As depicted in Figure 
3E, this antibody treatment did not result in further reduction of D2A1 cell clearance beyond 
the reduction observed in 4T1 mice that had not been depleted of NK cells. Accordingly, the 
ability of NK cells to kill the intraluminal tumor cells was already significantly impaired in 
4T1 mice in a manner that could not be further reduced by the NK-depleting antibody.
Yet other observations provided further support for the notion that neutrophils protect cancer 
cells in intraluminal sites from NK-mediated clearance. To explore this further, we made use 
of YAC-1 cells, which are established targets of NK-mediated clearance (42), and indeed 
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found YAC-1 clearance was NK cell-dependent, since depletion of NK cells using anti-
asialo-GM-1 antibodies resulted in a 4.5-fold increase in the number of YAC-1 cells found in 
the lung 4 hours after intravenous injection (Fig. 3F). Moreover, the clearance of YAC-1 
cells was inhibited when injected into 4T1-bearing mice relative to control mice (Fig. 3F). 
Importantly, consistent with our results with D2A1 cells (Fig. 2G), the protection of YAC-1 
cells from NK-mediated clearance in 4T1-bearing mice was dependent upon neutrophils, as 
neutrophil depletion abrogated any protective effects in these mice (Fig. 3G). These 
observations, when taken together, allowed us to conclude that neutrophils mobilized in 
4T1-bearing mice protect tumor cells from NK-mediated clearance, thereby prolonging their 
survival in the circulation and increasing the number of cells that could, in principle, 
subsequently form metastases.
We also undertook to further characterize the mechanism by which neutrophils inhibited the 
NK-mediated clearance of circulating D2A1 cells. The observed differences in NK activity 
between 4T1 mice and control non-tumor-bearing hosts did not result from a reduction in the 
numbers of circulating NK cells, as we detected similar numbers of NK cells in the lungs of 
both groups of mice. This strongly suggested that the reduced NK-mediated clearance 
resulted from a decrease in the functionality of individual NK cells.
To address this possibility, we employed a commonly used measure to gauge NK cell 
function by examining NK cell responsiveness ex vivo. This was assayed by functional 
activation of NK cells obtained from the lungs and spleens of 4T1 tumor-bearing mice and 
from control naïve mice. Thus, we used plate-bound antibodies specific for the NKG2D or 
NKp46 NK-activating receptors, or control IgG, followed by flow cytometry to assess 
intracellular IFN-γ production and degranulation (indicated by CD107a expression) (43, 44). 
As depicted in Figure 3H, 5% of the NK cells of control naïve mice were CD107+/IFN-γ+ in 
response to NKG2D stimulation and 10-12% of the NK cells were CD107+/IFN-γ+ in 
response to NKp46 stimulation. In contrast, in NK cells obtained from spleens or lungs of 
4T1 mice a >3-fold reduction in the percent of cells that were responsive to receptor 
stimulation was observed; <1.5% of NK cells were CD107+/IFN-γ+ in response to NKG2D 
stimulation (similar to baseline levels obtained from stimulation with IgG control) and <4% 
of the NK cells were CD107+/IFN-γ+ in response to NKp46 stimulation (Fig. 3H). Together 
with earlier data, these results argued that the unique systemic response provoked by 4T1 
tumors, namely the expansion and mobilization of neutrophils, led in turn to inhibition of the 
ability of NK cells to undergo functional activation and thereby attenuated the NK cell-
mediated clearance of intraluminal tumor cells.
 Neutrophils promote extravasation of intraluminal tumor cells
Extravasation is a crucial step in metastasis formation (45). Having confined the effects of 
neutrophils on metastasis to stages after intravasation and prior to colonization of the lung 
parenchyma, we considered whether neutrophils might facilitate extravasation of tumor cells 
from the lumina of pulmonary microvessels. We had previously observed that neutrophils 
increase the number of D2A1 cells surviving in the lungs 24 hours after their intravenous 
injection (Fig. 2G), but the proportion of extravasated carcinoma cells relative to those 
retained within the lumina of microvessels remained unknown. To examine this in more 
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detail, we injected human breast cancer cells (MDA-MB-231) intravenously into NOD/
SCID mice. Two hours later, we intravenously injected a human-specific HLA-A2 antibody 
that binds to class I MHC displayed by MDA-MB-231 cells. This protocol enabled us to 
label only cells of human origin, and only those present in the vascular lumen, but not breast 
cancer cells that had already extravasated.
Two hours after their injection, 70% of the MDA-MB-231 cells that were still present in the 
lungs of 4T1 mice were unstained by the antibody, suggesting that they had already 
extravasated from intraluminal sites and had therefore invaded the lung parenchyma. In 
contrast, only 30% of cancer cells retained in the lungs of the naïve mice had, as gauged by 
lack of antibody staining, escaped from the lumina and arrived in the parenchyma (Fig. 4A). 
This indicated that within two hours of i.v. injection, a significantly higher proportion of the 
MDA-MB-231 tumor cells had extravasated from the luminal to the parenchymal side of 
endothelial walls in the 4T1 mice relative to their behavior in naïve mice. Hence, neutrophils 
mobilized by 4T1 cells accelerated the kinetics of extravasation of carcinoma cells that had 
previously lodged within pulmonary microvessels.
 Neutrophils facilitate extravasation of tumor cells in an MMP-dependent manner
We undertook to study in more detail the mechanism(s) by which extravasation of 
intraluminal carcinoma cells was enhanced by the presence of splenocytes. Thus, we asked 
whether conditioned medium from splenocytes would enhance transendothelial migration in 
an in vitro model, in which transwell-permeable filter inserts were coated with either bEnd.3 
murine endothelial cells or human umbilical vein endothelial cells (HUVECs). Conditioned 
medium from splenocytes of tumor-free mice slightly increased the transendothelial 
migration of D2A1 cells relative to unconditioned medium, whereas medium conditioned by 
splenocytes from 4T1-tumor-bearing mice led to a 3-fold increase in the ability of D2A1 
cells to traverse the endothelial sheet of HUVECs (Fig. 4B, 4C). Similar results were 
obtained when the transwell membranes were coated with bEnd.3 murine endothelial cells 
and when the migration of B16-F10 tumor cells was tested (Fig. 4D). These observations 
demonstrated that splenocytes from 4T1-bearing mice secrete soluble factors that enhance 
transendothelial migration of cancer cells.
The work described above had allowed us to associate most of the systemic effects of 4T1 
cells to the mobilization specifically of neutrophils. Moreover, the percentage of CD11b+/
Ly6G+ neutrophils within the splenocyte population was substantially elevated (21 fold) in 
4T1 mice relative to naïve mice (Supplementary Fig. 4). Accordingly we wished to confirm 
that neutrophils, were responsible for facilitating transendothelial migration of cancer cells. 
To do so, we enriched for Ly6G+ neutrophils from the spleens of 4T1 mice and collected 
conditioned medium from these cells as well as from unfractionated splenocytes containing 
an equal number of neutrophils. In fact, the medium conditioned by the Ly6G+-enriched 
splenocytes from control mice increased transendothelial migration of D2A1 cells to a 
similar extent as the medium conditioned by unfractionated splenocytes prepared from 4T1 
mice (Fig. 4E). Hence, Ly6G+ neutrophils present in the spleens of 4T1 mice were indeed 
responsible for the lion's share of the observed enhanced transendothelial migration.
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We undertook to determine whether neutrophils from 4T1-bearing mice were qualitatively 
different from normal neutrophils in their ability to promote transendothelial migration. To 
do so, we enriched splenocytes from non-tumor-bearing naïve mice for Ly6G+ neutrophils. 
Conditioned medium from these cells increased transendothelial migration of D2A1 cells to 
the same extent as did medium conditioned by comparable numbers of Ly6G+ cells prepared 
from 4T1-mice (Fig. 4F). Therefore, individual neutrophils from tumor-bearing and non-
tumor-bearing mice were equally competent to facilitate extravasation, and the cell-
biological effects of splenocytes from tumor-bearing mice, including the enhanced 
transendothelial migration described above (Fig. 4D), reflected an expansion in the numbers 
of neutrophils and therefore a corresponding amplification of their normal intrinsic 
biological properties.
We undertook to identify the soluble factors secreted by neutrophils that enhanced the 
transendothelial migration of the tumor cells. Using antibody arrays, we found higher levels 
of secretion of two proteases, MMP-8 and MMP-9, in splenocytes from 4T1 mice relative to 
the medium conditioned from the same number of splenocytes extracted from naïve mice. 
These findings were further verified by ELISA (Fig. 4G). Inhibition of MMP-8 with either a 
specific small molecule inhibitor or a neutralizing antibody reduced the rate of 
transendothelial migration to basal levels observed in unconditioned medium (Fig. 4H). An 
anti-MMP-9 antibody also reduced by more than 50% the ability of splenocyte-conditioned 
medium to enhance transendothelial migration (Fig. 4H). Overall, these results indicated that 
splenocyte-secreted MMP-8 and MMP-9 played an important role in mediating the in vitro 
trans-endothelial cell migration of tumor cells. Importantly, high levels of MMP-8 and 
MMP-9 were secreted into the medium by Ly6G+ neutrophils (data not shown), further 
emphasizing the key role of neutrophils in promoting metastasis by aiding tumor cell 
extravasation.
As reported by others (11, 12, 33) , we noted the abundant expression of MMP-9 in the 
lungs of 4T1 tumor-bearing mice but not in those of control mice. Furthermore, the MMP-9 
is expressed by Ly6G+ neutrophils (Fig. 4I). We employed MMP-9 knockout (KO) mice 
(46) to further dissect the contribution of this particular protease to metastasis using isogenic 
B16-F10-G-CSF rather than 4T1 cells to mobilize neutrophils in the C57BL/6 genetic 
background. Equal numbers of the splenocytes from these tumor-bearing wild type (WT) 
and MMP-9 KO host mice were then injected into recipient mice followed by i.v. injection 
of B16-F10-GFP+ cells (1 hour later). As expected, the adoptive transfer of WT splenocytes 
into WT recipient mice resulted in a 5-fold increase in metastasis relative to control mice 
that did not receive splenocytes. In contrast, no significant increase was observed following 
adoptive transfer of MMP-9 KO splenocytes into MMP-9 KO recipient mice. Importantly, 
when MMP-9 wild-type splenocytes were transferred into MMP-9 KO recipient mice - a 5-
fold increase in B16-F10 lung metastases was noted, similar to the effect achieved by 
adoptive transfer of WT splenocytes into WT recipient mice (Fig. 4J). This indicated that the 
splenocyte-derived protease MMP-9 played a major role in facilitating transendothelial 
migration both in vitro and, more importantly, in vivo, the latter process contributing to 
enhanced formation of metastases. These data collectively argue that, in addition to their role 
in suppressing NK cell-mediated clearance of tumor cells, neutrophils promote metastasis by 
enhancing the extravasation of these cells.
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 Neutrophil-secreted IL-1β activates endothelial cells and facilitates migration
The enhanced extravasation clearly involved an interplay between three cell types – the 
extravasating tumor cells, the neutrophils, and the endothelial cells. To further dissect 
components of this crosstalk, we first looked for a direct effect of the neutrophils on either 
the tumor cells or the endothelial cells individually. To test this, we conducted experiments 
in which only the D2A1 tumor cells or the endothelial cells were pre-treated with the 4T1 
splenocyte-conditioned medium for 3 hours. The pre-treated cells were washed to remove 
any residue of the conditioned medium prior to the addition of these D2A1 cells to the top 
chamber of transwells in which the membranes had been coated with endothelial cells. This 
protocol contrasts with that employed in the experiments depicted in Figure 4B, in which the 
migration occurred in the presence of conditioned medium. As indicated in Fig. 5A, 
pretreatment of the D2A1 cells alone did not increase their ability to migrate through the 
endothelial cell layer. In stark contrast, pre-treatment of murine endothelial bEnd.3 cells 
with the 4T1-splenocyte-conditioned medium indeed sufficed to increase transendothelial 
migration of D2A1 cells (Fig. 5B). Furthermore, incubation of bEnd.3 cells with 4T1-
splenocyte-conditioned medium induced expression and secretion of MMP-9 by the 
endothelial cells, augmenting that initially produced by the neutrophils (Fig. 5C, and 
Supplementary Fig. 5A, 5B). These results suggest that the enhanced extravasation does not 
result from a direct effect of the neutrophils on the migrating tumor cells but instead through 
the modulation of the endothelial cell barrier.
Immune cells impact their surroundings through the secretion of cytokines and chemokines. 
More specifically, IL-1β is a cytokine that is known to be secreted by neutrophils, to activate 
endothelial cells, and to increase leukocyte extravasation (16). We therefore tested whether 
IL-1β plays a role in the activation of the endothelial cells in our system, and indeed, a 2-
fold increase in transendothelial migration of D2A1 cells was observed when IL-1β was 
added to RPMI medium (Supplementary Fig 5C). Furthermore, ~4-fold higher levels of 
IL-1β were secreted into the conditioned medium by splenocytes from 4T1 mice compared 
to splenocytes from control Balb/c mice (Fig. 5D). Importantly, the levels of IL-1β secreted 
by Ly6G+ neutrophils (enriched from spleens of 4T1 mice) were similar to those secreted by 
the 4T1 splenocyte population, pointing once again to the important role neutrophils play in 
IL-1β−mediated responses. Moreover, transendothelial migration in vitro was reduced when 
an IL-1 receptor antagonist was added to conditioned medium from splenocytes obtained 
from 4T1 mice (Fig. 5E). Furthermore, upon addition of an IL-1 receptor antagonist to the 
conditioned medium, MMP-9 secretion by endothelial cells following treatment with 4T1 
splenocyte-conditioned medium was inhibited (Fig. 5F). Taken together, these observations 
indicated that neutrophil-secreted IL-1β acts directly to activate the endothelial cells, 
ostensibly amplifying the effects of the already-high levels of MMP-9 found in the 4T1-
splenocyte-conditioned medium.
 Activated endothelial cells enable expedited protrusion formation by intraluminal tumor 
cells
To further decipher precisely how activated endothelial cells enable enhanced 
transendothelial migration, we employed an in vitro assay featuring perfusable 
microvasculature formed in micro-devices (47). In this model, HUVECs are suspended in a 
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fibrin/collagen type I matrix and interconnected vascular networks are formed via a 
vasculogenic-like process over a period of 4 to 5 days in micro-devices. In this assay, tumor 
cells can be infused and are found to arrest via physical trapping, mimicking the in vivo 
process. Extravasation rate was quantified via confocal microscopy at 20X and scored as the 
subset of cells that had completely traversed the endothelial barrier (Fig 6A).
HUVEC networks were treated with 4T1-splenocyte-conditioned medium (or control RPMI) 
for 4 hours prior to addition of human MDA-MB-231 cells to the devices. We found that 
16.2% of MDA-MB-231 human breast cancer cells extravasated from the microvessels 
formed by control HUVECs within 3 hours. This extravasation efficiency was increased ~2.5 
fold when HUVEC cells were pre-treated with 4T1-splenocyte-conditioned medium (Fig. 
6A and 6B).
In order to study and understand the transendothelial migration of the tumor cells in further 
detail, we tracked the transendothelial migration of MDA-MB-231 cells using time-lapse 
confocal microscopy. We first noted that the initial sign of transendothelial crossing of tumor 
cells appeared as small protrusions extending from the cell bodies of these carcinoma cells 
through the endothelial layer.
Analysis of image sequences of transmigrating MDA-MB-231 revealed that the time 
required for tumor cells to extend the first initial, discernible protrusion through the 
endothelial wall was significantly shorter when HUVECs were pre-treated with 4T1-
splenocyte conditioned medium (compared to RPMI medium control). Thus, following 
pretreatment of HUVECs with 4T1-splenocyte-conditioned medium, ~ 5% of MDA-
MB-231 had already extended protrusions after 15 minutes following tumor perfusion, 
whereas the same degree of protrusion formation occurred in control treated devices only 
after one hour (Fig. 6B). The average time for the first observed protrusion was ~ 30 minutes 
for 4T1-conditioned medium treated HUVECs, compared to ~ 90 minutes for the control 
RPMI (Fig. 6C). However, the time required for MDA-MB-231 cells to migrate across the 
endothelial cell layer – i.e., the amount of time required for a cell from the first observable 
protrusion until complete translocation across the endothelial barrier, was not different 
between treated vs. un-treated HUVEC cells (~ 50 minutes) (Fig. 6D).
These results further strengthen the findings reported above demonstrating that the 
neutrophils facilitate the migration of tumor cells in an indirect manner – not through a 
direct effect on the tumor cells but rather through their activation of endothelial cells, which 
in turn expedite the initiation of transendothelial crossing by tumor cells.
 DISCUSSION
As the biological complexity of tumor growth and metastasis is explored in greater detail, it 
has become apparent that key aspects of tumor biology can only be explained by a detailed 
understanding of how various types of host cells contribute to tumor progression. The work 
presented here describes how recruited host cells can affect the behavior of cancer cells that 
have traveled from primary tumors to a distant anatomical site, specifically the lungs. Such 
effects, by necessity, reflect changes in the systemic physiology of tumor-bearing hosts and 
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govern later steps of the invasion-metastasis cascade. More specifically, we find that Ly6G+ 
neutrophils can increase metastatic seeding in at least two distinct ways: (i) by inhibiting NK 
cell cytotoxic activity, the neutrophils can protect intraluminally trapped tumor cells from 
rapid clearance by these innate immune cells, and (ii) by expediting extravasation. Both of 
these mechanisms contribute to the ultimate formation of metastases by increasing the pool 
of tumor cells that succeed in entering the lung parenchyma, placing them in sites where 
they are poised to generate micrometastases and, subsequently, macroscopic metastases (Fig. 
6E).
Previous reports have suggested that tumors are able to modify the distant microenvironment 
prior to arrival of metastatic cells, doing so by creating a ‘premetastatic niche’ (48-50). In 
this ‘pre-metastatic niche’ model, bone marrow-derived cells were reported to arrive in the 
lung parenchyma days before tumor cells and create a more hospitable environment that 
facilitates colonization and subsequent formation of macroscopic metastases. We 
demonstrate here a quite different mechanism, in which the accessory effects of neutrophils 
operate only in a relatively short window of time during which neutrophils suppress the 
otherwise-rapid NK-mediated clearance of intraluminally trapped carcinoma cells and 
facilitate the extravasation of these cells through effects on endothelial cells.
Our observations demonstrate a clear pro-metastatic role for the Ly6G+ neutrophils and are 
supported by other reports showing that Gr1+-CD11b+ cells alter the overall landscape of the 
metastatic lung and tip the balance of immune protection in favor of tumor promotion (12, 
33). Others have shown an anti-metastatic effect for neutrophils in 4T1 tumor-bearing mice 
(11). These anti-metastatic properties were demonstrated in neutrophils that accumulate in 
the lung prior to metastasis formation (i.e., up to day 10 after initial 4T1 tumor 
implantation), whereas our own work examines these dynamics in a later phase when 
implanted tumor cells have already formed significant primary tumors and have proceeded 
to seed and colonize distant tissues (14-31 days after 4T1 tumor implantation). The role of 
neutrophils in metastasis may be context dependent, and it is plausible that the early tumor-
entrained neutrophils and their later counterparts exert opposite functions on metastatic 
progression in the lungs. Further studies may shed light on the role of neutrophils in the 
formation of various types of metastases.
While our present results demonstrate that Ly6G+ neutrophils directly promote pulmonary 
metastasis of cancer cells through at least two distinct mechanisms, it remains possible that 
other types of innate immune cells promote metastasis in other cancers and anatomical sites 
by acting through alternative mechanisms. For example, recent studies have reported a role 
for the cytokine CCL2 in promoting metastasis in models of breast and colon carcinoma 
through recruitment of monocytes to the lung (51, 52) as well as by activating endothelial 
cells, doing so by signaling through their CCR2 receptors (53). Platelets have also been 
shown to play a role in facilitating metastasis through the secretion of CXCL5 and CXCL7 
which recruit granulocytes to sites of intraluminally trapped tumor cells (54). Altogether, 
these results point to the complexity of the intraluminal survival and extravasation steps, in 
which different types of immune cells, cytokines and proteases appear to participate.
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Tumor cells have been shown to recruit immune-suppressive cells that erect a protective 
barrier against immune attack (55-58). These suppressive actions have been studied mostly 
in the context of the monocyte/macrophage subset of CD11b+/Gr1+ myeloid cells and their 
role in suppression of T-cell-mediated responses (59, 60). The fact that we observed 
comparable effects in immune-competent mice as well as immune-deficient NOD/SCID 
mice indicates that the mechanism of action in our model system utilizes a different type of 
immune suppression. Furthermore, our data highlight an immunosuppressive role that is 
unique in two aspects: 1) the immune cells involved – neutrophils – act through their 
inhibition of NK-mediated clearance of cancer cells; and 2) the time frame of the 
immunosuppression – during a short window of time beginning with the arrival of 
disseminated cancer cells in the microvessels of a target organ, in this case the lung.
The present results show that the neutrophils activate and induce changes in endothelial cells 
leading to increased extravasation through the action of MMP-9. An additional mechanism 
for this direct activation of endothelial cells might well be mediated through vascular 
endothelial growth factor (VEGF). While several proteinases are capable of releasing VEGF 
from the extracellular matrix, MMP-9 is especially efficient in this regard (61, 62). Along 
these lines, the increase in MMP-9 levels that we observed in splenocyte-conditioned 
medium from 4T1 mice was accompanied by a concomitant increase in the levels of VEGF 
(compared to splenocyte-conditioned medium from control naïve mice; data not shown). 
This crosstalk between neutrophils and endothelial cells and the specific roles of MMP-9 
and VEGF in facilitating extravasation warrants further research.
4T1-induced tumors represent a widely used model system in mice used to study metastasis. 
The effects of the neutrophilia that we observed in tumor-bearing mice are consistent with 
clinical data showing that either elevated neutrophil counts or elevated neutrophil/
lymphocyte ratios serve as indicators of poor prognoses in a variety of cancers, including 
lung, pancreatic, ovarian, gastric, and colon carcinomas (63-67). Furthermore, elevated 
plasma G-CSF levels have been reported in a variety of solid tumors and found associated 
with severe leukocytosis and poor prognosis (68-72).
In oncologic practice, G-CSF is often used to overcome chemotherapy-associated 
neutropenia (73). Importantly, the present findings and those of others (12, 14) suggest that 
such G-CSF may, in certain circumstances, actually serve to facilitate tumor metastasis. In 
particular, our data indicate that G-CSF administration has pro-metastatic effects not only in 
the case of prolonged exposure to high levels of G-CSF secreted by the primary tumor but 
even following short-term (5 days) systemic administration of this cytokine. Other reports 
have shown in experimental mouse models that overexpression of G-CSF by tumors has a 
deleterious impact on therapeutic outcome, since it mediates tumor refractoriness to anti-
VEGF therapy (14). While it may be necessary to administer G-CSF to overcome the acute 
neutropenia of certain patients, identifying and eliminating specific tumor-promoting 
activities induced by G-CSF may eventually yield more beneficial clinical outcomes for 
cancer patients suffering neutropenia.
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 METHODS
 Cell Culture
All cells were cultured in 5% CO2 humidified incubator at 37° C. Mouse mammary 
carcinoma cell lines 4T1 (ATCC) and D2A1 (gift from F. R. Miller) were grown in RPMI 
supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 U/ml penicillin, and 
100 μg/ml streptomycin (Invitrogen). Murine endothelial, B.end3 cells were grown in 
Dulbecco's Modified Eagle (DME) medium, supplemented with 10% FBS, 100 U/ml 
penicillin, and 100 μg/ml streptomycin. Human umbilical vein endothelial cells (HUVECs) 
were propagated in endothelial cell basal medium (EBM) with 0.1% human epidermal 
growth factor (hEGF), 0.1% hydrocortisone, 2% FBS, 0.4% bovine brain extract (BBE), 30 
μg/ml Gentamicin, and 15 ng/ml Amphotericin. MDA-MB-231 cells were grown in 
DME/F12 supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. 
B16-F10 cells were grown in DME medium supplemented with 10% heat inactivated FBS, 
100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). YAC-1 cells were grown in 
RPMI supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin 
(Invitrogen). In experiments testing in vitro extravasation in microvasculature networks, 
HUVECs stably expressing GFP (Angioprotemie) were cultured in EGM-2MV medium 
(Lonza) and used at passage 4 to 6. Normal human lung fibroblasts (Lonza) were cultured in 
complete FGM (Lonza) and used between passages 4 to 8. Cells that were stably infected 
with GFP or tdTomato were done so as previously described (36). In order to overexpress G-
CSF, lentiviral vectors expressing the G-CSF protein coding DNA (MMM1013-99829324; 
Open Biosystems) were generated using the pLV-IRES-neo as a backbone. D2A1 and B16-
F10 cells were then infected with the lentiviral vectors. Cell lines were not authenticated 
prior to use.
 Animals
All research involving animals complied with protocols approved by the MIT Committee on 
Animal Care. BALB/c mice, C57/BL6 mice and CB6F1 mice (a cross between BALB/c and 
C57BL/6) were obtained from Jackson Laboratory. A colony of NOD-SCID mice was 
maintained in-house. The MMP-9 KO mice (Stock # 007084) were originally obtained from 
the Jackson Laboratory.
 Tumor models
For primary tumor formation, 2.5 × 105 4T1, D2A1 or B16-F10 tumor cells were injected 
subcutaneously (s.c.) in their growth medium with 20% Matrigel into 10 to 14-week old 
female syngeneic BALB/c or C57BL/6 (for B16-F10 cells) mice. For contralateral 
injections, 2.5 × 105 4T1 tumor cells were injected subcutaneously on the right, and at the 
same time, 2.5 × 105 D2A1-Tom+ tumor cells were injected subcutaneously on the left side 
of the same mouse. For intravenous (i.v.) injections 2 × 104 cells were injected in 100 μl 
volume into mice. Splenectomy was performed as previously described (34). Five hours 
after splenectomy tumor cells were injected subcutaneously. The contralateral experiments 
and the splenectomy experiments were terminated 4-5 weeks after tumor cell implantation, 
at which time leukocyte mobilization as well as pulmonary metastasis were scored.. In 
experiments assessing lung macrometastatic formation following i.v. injection D2A1, B16-
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F10 and MDA-MB-231 cells (2 × 104) were injected i.v. into BALB/c mice (for D2A1 cells) 
or NOD/SCID mice (for B16-F10 and MDA-MB-231 cells) implanted with 4T1 cells 2 
weeks earlier (or control non-tumor bearing mice) experiments were terminated and 
metastasis was scored 14 days later. In experiments testing short term retention of tumor 
cells (NK clearance and extravasation; 2-24 hours after i.v. injection), the cells were injected 
into mice implanted with 4T1 cells 4 weeks earlier (or control non-tumor bearing mice). In 
compliance with veterinary guidelines, experiments in which C57BL/6 mice were implanted 
with B16-F10-GCSF cells (or B16-F10 cells overexpressing control vector) were terminated 
3 weeks post tumor cell implantation.
 Splenocyte and neutrophil adoptive transfer
In experiments involving adoptive transfer of splencoytes or Ly6G+ neutrophils, spleens 
were removed from donor mice and homogenized into a single-cell suspension using a 3 ml 
syringe plunger and 40 μm cell strainer (BD Falcon). Thereafter, splenocytes were passed 
through a 40 micron filter basket prior to injection. In experiments involving adoptive 
transfer of neutrophils, splenocytes were enriched for Ly6G+ neutrophils using the MACS 
cell separation kit (Miltenyi Biotec) according to manufacturer's instructions. Mice were 
injected i.v. with 2 injections of splenocytes (2.5-3 × 107) or Ly6G+ neutrophils (5-6 × 106) 
suspended in 200 μL medium per injection, 45 minutes apart (control mice were injected 
with vehicle). D2A1-Tom+ cells or B16-F10-GFP+ cells (2 × 104 cells in 100 μl medium) 
were injected i.v. 45 minutes after the last splenocyte or neutrophil injection.
 Quantification of Lung Metastases
For visualizing cancer cells that had disseminated in the lung tissue, lungs were harvested 
from the injected mice, dissected into the five lobes and analyzed under a fluorescence 
dissection microscope (Leica MZ12) for the presence of tdTomato+- or GFP+-labeled 
microscopic and/or macroscopic lung metastases. The quantification of cells retained in the 
lungs 10 minutes, 1 hour, 2 hours, 4 hours or 24 hours after i.v. injection was performed by 
directly counting the numbers of GFP+ cells or tdTomato+ cells in the lung under a 
fluorescence dissection microscope (Leica MZ12). For quantification of lung metastases in 
mice carrying unlabeled 4T1 tumors, lungs were fixed in 10% formalin, embedded in 
paraffin, sectioned and stained with hematoxylin and eosin. Yac-1 cells were labeled with 
Cell Trace CFSE (Life Technologies) prior to intravenous injections (2 × 104 cells) 
according to according to manufacturer's instructions.
 In vivo imaging
Bioluminescence imaging of luciferase activity was used to monitor cancer cell clearance 
with a Xenogen IVIS system under 2.5% isoflurane anesthesia at the indicated time points as 
described. Imaging of mice was performed by injection of D-luciferin (165mg/kg of body 
weight, intraperitoneal (i.p.) injection; Caliper Life Sciences), 10 minutes before 
bioluminescence imaging. Images were analyzed using Living Image Software version 4.3.1 
(Caliper Life Sciences).
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 NK and neutrophil depletion
To deplete NK cells, anti-asialo GM-1 (20 μl per mouse, clone Poly21460; Biolegend) or 
anti NK1.1 (cat # BE0036; Bioxcell) antibodies were injected i.p. one day prior to tumor cell 
injections. Matching isotype Rabbit polyclonal IgG (AB-105-C; R&D Biosystems) served as 
control. To deplete neutrophils, anti-Ly6G antibody (200 μg per mouse, clone 1A8; 
Bioxcell) was injected i.p. one day prior to tumor cell injections. Matching isotype Rat 
IgG2A (MAB006; R&D Biosystems) served as control.
 In vivo extravasation
In vivo extravasation assay was done as previously described (74). FITC-conjugated anti-
human HLA-2 antibody (20 μg/mouse, clone BB7.2; BD Biosciences) was injected i.v. into 
NOD/SCID mice two hours after i.v. injection of 1 × 105 MDA-MB-231-Tom+ cells. Lungs 
were harvested 10 minutes after injection of antibody, digested with collagenase A (1.5 mg/
ml), hyaluronidase (125 u/ml) and DNAse (0.1 mg/ml) for 1 hr at 37° C. Resulting cell 
suspensions were filtered through 70 μm pore-size nylon meshes. Cells were incubated in 
the presence of saturating amounts (10 μg/sample) of unlabeled anti-HLA-A2 Ab for 30 
minutes. The percentage of MDA-MB-231-Tom+ cells that were labelled with FITC-HLA-
A2 antibodies was determined by flow cytometry.
 In vivo G-CSF administration
To assess the effects of G-CSF on metastasis, BALB/c mice were injected s.c. with rhG-CSF 
(250 mg/kg; Neupogen, Amgen) daily for five consecutive days. Control animals were given 
PBS as a vehicle. Five hours after the last G-CSF injection, 2 × 104 D2A1 cells were 
injected i.v.. In other experiments, the effect of adoptive transfer of splenocytes from G-CSF 
treated mice was tested. Five hours after the last G-CSF injection, spleens were harvested 
from G-CSF-treated mice (or control PBS-treated mice) and adoptive transfer into recipient 
BALB/c mice followed by i.v. injection of D2A1 cells was done as previously described in 
‘splenocyte adoptive transfer’ section.
 Preparation of splenocyte - conditioned media
Splenocyte-conditioned media were prepared from 1.5 × 107 freshly isolated unsorted 
splenocytes or from the Ly6G+ enriched subpopulation. These freshly isolated cells were 
plated in the presence of 10 ml RPMI medium (supplemented with 10% heat-inactivated 
FBS, 100 U/ml penicillin and 100 μg/ml streptomycin) for 48 hours at 37°C, 5% CO2 in a 
humidified incubator. Subsequently the conditioned medium was collected and the cells 
were removed by centrifugation. The supernatant was collected and sterile filtered through a 
0.2 μm Acrodisc filter (PALL Biosciences).
 ELISA and protein arrays
Plasmas and conditioned media were analyzed for mouse G-CSF (MCS00; R&D Systems), 
IL-1β (MLB00B; R&D Systems), MMP9 (MMP900B; R&D Systems) and MMP-8 (Uscn 
Life science Inc.) according to manufacturer's instructions. Conditioned media from 
splenocytes or tumor cell lines were analyzed for the secretion of various proteins using 
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mouse angiogenesis array (ARY015; R&D Systems) and mouse cytokine array (ARY006; 
R&D Systems) according to manufacturer's instructions.
 In vitro transendothelial migration assay
The upper surface of 8μm polyester Transwells (PET; corning) was coated with 5 × 104 
mouse endothelial cells for 24 hours at 37° C in complete bEnd.3 mEC media (100 μL in the 
upper chamber and 500 μL in the lower well). Once the endothelial cell layer had been 
established, tumor cells (5 × 104) were added to the upper chamber. The lower 
compartments of the wells were filled with RPMI medium (supplemented with 10% FBS) or 
splenocyte-conditioned media (prepared as described above). In the inhibition experiments, 
5 ng/ml IL-1β receptor antagonist (Prospec), 1 μg of anti-MMP-9 antibody (ab38898; 
Abcam) or anti-MMP-8 antibody (ab53017; Abcam) was added to the upper chamber. 
MMP-8 inhibition on the transendothelial migration of D2A1 tumor cells was also tested 
using 10, 50 or 100 μM of MMP-8 inhibitor-1 (Calbiochem); wells supplemented with 
RPMI containing 0.1 % DMSO were included in the analysis as controls. For the pre-
conditioning experiments, D2A1-Tom+ cells or mouse endothelial cells were treated with 
conditioned medium from splenocytes obtained from naïve BALB/c or 4T1mice, or RPMI 
(control) for 4 hours. The pre-treated endothelial cells or D2A1-Tom+ cells were washed in 
PBS to remove any residue of the conditioned medium prior to the addition of D2A1 cells to 
the top chamber of transwells. Migration was assessed after 4h at 37° C in 5% CO2. The 
cells from the upper surface of the well were wiped off with PBS, and the number of 
migrated cells were counted in 4 fields. Experiments were repeated at least 5 times and 
performed in duplicates or triplicates.
 Microvascular network extravasation assay
Perfusable in vitro microvascular networks were generated in microfluidic devices as 
described previously (47). Briefly, HUVECs and normal human lung fibroblasts were 
resuspended in fibrin gels at 6×106 cells/mL and 3×106 cells/mL, respectively, and injected 
into micro channels. Devices were then cultured in EGM-2MV for 4 days at 37° C in 5% 
CO2, after which lumens formed and became perfusable. Four hours prior to tumor cell 
injection, media in devices were changed to splenocyte conditioned media or control RPMI. 
Then, MDA-MB-231 Td Tomato were resuspended to 5×105 cells/mL in either conditioned 
media or RPMI (Company) and perfused into corresponding devices via a hydrostatic 
pressure drop. Devices were transferred to an environmental chamber equipped confocal 
microscopy (Olympus FV1000). Time-lapse images were taken every 15 minutes for at least 
4 hours at 20X magnification and z-steps of 1.7 um. Images were analyzed using Imaris 
Bitplane software. A cell is defined as extravasated when the entire cell body has cleared the 
lumen, based on the orthogonal views given in Imaris. As soon as a cell becomes partially 
translocated past the lumen, it is defined as “protrusive.” The same individual cells were 
followed over a time period of 4 hours. Data was collected from >150 cells per condition, 
over 3 independent experiments.
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 White blood cell counts in peripheral blood
To obtain peripheral white blood cell counts, mice were bled retro-orbitally. For white blood 
cell counts, an aliquot was diluted 1:10 in 1X PBS and processed at the MIT Division of 
Comparative Medicine.
 Flow cytometry
Cells were labeled for flow cytometry by incubation with the following fluorophore-
conjugated antibodies: CD3 perCP-Cy5.5(17A2; Biolegend), Cd49b PE (DX5; Biolegend), 
NKp46 APC (29A1.4; Biolegend), CD11b FITC (M1/70; eBioscience), Ly6G PE (1A8; BD 
Pharmingen), G-CSF Receptor (S1390; Abcam), CD107a (1D4B; Biolegend). Flow 
cytometric analyses were carried out on a fluorescent -activated cell sorting (FACS) Fortessa 
(BD Biosciences) using BD FACSDiva Software.
 Ly6G+ neutrophil Enrichment
Spleens of tumor-bearing and control mice were homogenized with the GentleMACS 
(Miltenyi Biotech), according to the manufacturer's instructions in order to obtain a single -
cell suspension. Splenocytes were counted, and 1-2 × 108 cells were enriched for Ly6G+ 
cells using magnetic beads (130-092-332, Miltenyi Biotech) according to manufacturer's 
instructions. The purity of the Ly6G+ population was assessed by FACS analysis.
 Ex vivo degranulation assay
Wells of flat-bottomed, high-protein binding plates (Thermo Fisher Scientific) were coated 
with 0.5 μg of anti-NKG2D antibody (MI-6) or with 0.5 μg of anti-NKp46 antibody 
(29A1.4) or rat IgG2a as a control. 106 cells per well were stimulated for 5 hours in the 
presence of 1 μg of Golgi Plug (BD), 1 μg of Golgi Stop (BD), 100 U of recombinant human 
IL-2 (Roche), and anti-CD107a (1D4B) mAb antibody.
 Immunofluorescence
Serial frozen sections (6 μm) were prepared and immunofluorescence staining was carried 
out for histological analysis. After blocking the sections with 4% normal goat serum in PBS 
at room temperature for 30 minutes, MMP9 antibody (ab38898, Abcam) was incubated at 
4°C overnight followed by Alexa Fluor 594 goat anti-rabbit IgG or Alexa Fluor 647 anti-
rabbit IgG antibody (A11037 and A21245, Life Technologies). For double 
immunofluorescence staining, anti-Ly-6G antibody (clone: 1A8, BioLegend) was incubated 
at room temperature for 1 hour followed by Alexa Fluor 488 goat anti-rat IgG (H+L) 
antibody (A11006, Life technologies). Nuclei were stained with DAPI using 
VECTASHIELD Mounting Medium (H-1200, Vector Laboratories, Inc.) and images were 
captured using BX63 (Olympus) equipped with ANDOR Neo sCMOS Monochrome 
Camera (Andor Technology Ltd.). The images were processed using ImageJ software.
 Statistical Analysis
All of the data are presented as the mean ± standard errors of mean (SEM). An unpaired 
two-tailed Student's t test was used to calculate the p values. A p value of less than 0.05 was 
considered significant.
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 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE
This study provides important insights into the systemic contributions of neutrophils to 
cancer metastasis by identifying how neutrophils facilitate intermediate steps of the 
invasion metastasis cascade. We demonstrate that neutrophils suppress NK cell activity 
and increase extravasation of tumor cells.
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Figure 1. Tumor metastasis is mediated by neutrophils
(A) Total leukocyte (WBCs) and neutrophil counts in blood from control non-injected mice 
or 4-5 weeks post-implantation with murine breast carcinoma 4T1 cells. n ≥ 9 mice for each 
group. (B) Representative picture (top) and average weight (bottom) of spleen from naïve 
BALB/c (control) or 5 weeks after s.c implantation of mice with 4T1 cells. n ≥ 8 mice for 
each group. (C) 4T1 tumor weight in sham-operated BALB/c mice (control) or 
splenectomized mice. n ≥ 17 for each group. (D) Number of 4T1 lung metastases (per 
hematoxylin & eosin-stained section comprising all five lobes) in mice implanted with 4T1 
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cells in sham-operated BALB/c mice (control) or splenectomized mice. n ≥ 12 for each 
group. (E) Representative picture of lung lobes from sham surgery or splenectomized mice. 
Red arrows point to lung metastases. (F) D2A1 primary tumor weight 4-5 weeks after s.c 
implantation of mice with D2A1 cells contralateral to 4T1 cells or Matrigel (control). n ≥ 19 
for each group. (G) D2A1 lung metastases (fold increase vs D2A1 injected contralaterally to 
Matrigel) in mice implanted with D2A1 cells contralateral to 4T1 cells or Matrigel (control). 
n ≥ 14 for each group. (H) D2A1 lung metastases (fold increase vs D2A1 injected 
contralaterally to Matrigel) in sham-operated or splenectomized mice implanted with D2A1 
cells contralateral to 4T1 cells. n ≥ 8 for each group. * indicates p< 0.05. (I) Total leukocyte 
(WBCs) and neutrophil counts in blood from mice 4-5 weeks post-implantation with D2A1 
cells ectopically expressing empty vector (control) or G-CSF. n ≥ 9 mice for each group. (J) 
D2A1 lung metastases spontaneously arising in mice bearing primary tumors of D2A1 cells 
ectopically expressing G-CSF or empty vector (control). n ≥ 7 for each group. (K) Number 
of D2A1-Tom+ metastases in lungs of mice lacking primary tumors 2 weeks after 
intravenous injection of D2A-Tom+ cells. Mice were injected with PBS, or anti-Ly6G 
antibody 24 hours before intravenous injection of cells. n ≥ 7 for each group. * indicates p< 
0.05.
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Figure 2. Neutrophils facilitate later steps of the invasion-metastasis cascade
(A) Lung metastasis (non-4T1) in mice injected i.v. with 2×104 D2A1-Tom+, B16-F10-
GFP+ or MDA-MB-231-Tom+ cells. Results show fold increase upon injection into 4T1 
tumor-bearing mice vs naive non-tumor-bearing mice (control). B16-F10-GFP+ and MDA-
MB-231-Tom+ cells were injected into NOD/SCID 4T1 tumor-bearing mice 14 days after 
implantation of 4T1 cells. Experiment was terminated 2-3 weeks later and lung metastases 
were quantified. n ≥ 8 for each group. (B) D2A1 lung metastases in mice (fold increase vs. 
control PBS injection) following adoptive transfer of splenocytes from non-tumor bearing or 
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4T1 tumor-bearing mice. n ≥ 9 for each group. (C) Number of D2A1-Tom+ metastases in 
lungs of G-CSF-treated mice compared to control (PBS-treated) mice. n ≥ 13 for each 
group. (D) Number of D2A1-Tom+ metastases in lungs following adoptive transfer of 
splenocytes from G-CSF-treated mice (fold increase compared to control mice that were 
injected with splenocytes from PBS-treated mice). n ≥ 12 for each group. (E) Number of 
D2A1-Tom+ cells in lungs of 4T1 (or naïve control) mice 24 hours post i.v. injection of 
D2A1 cells (left). Representative lung lobe images (right). 4T1 mice had been implanted 
with 4T1 cells 4 weeks earlier (F) Number of D2A1-Tom+ cells in lungs of mice i.v. 
injection of D2A1-Tom+ cells into either control naïve mice, or mice bearing primary tumors 
of D2A1 or B16-F10 cells ectopically expressing G-CSF (implanted 4 weeks earlier). n ≥ 6 
for each group. (G) Number of D2A1-Tom+ cells in lungs of mice (fold increase vs. control 
PBS injection) following adoptive transfer of Ly6G+-enriched neutrophils from splenocytes 
from 4T1 tumor-bearing mice. n ≥ 7 for each group. (H) D2A1-Tom+ cells in lungs (fold 
increase compared to control mice without primary tumors) of 4T1 mice 24 hours post i.v. 
injection of D2A1 cells. Mice were injected with PBS, IgG antibody or anti-Ly6G (1A8) 
antibody 24 hours before injection of cells. Non-tumor-bearing mice served as control. n ≥ 
10 mice per group. (I) Number of D2A1-Tom+ cells in lungs of non-tumor-bearing mice 24 
hours post i.v. injection of D2A1 cells. Mice were injected with PBS, control IgG antibody, 
or anti-Ly6G antibody 24 hours before i.v.injection of cells. n ≥ 11 for each group. For 
panels B, C & D - experiment was terminated and D2A1 lung metastases were quantified 2 
weeks after i.v. injection of D2A1 cells. For panels E, F, G, H & I - experiment was 
terminated 24 hours after i.v. injection of D2A1 cells and number of D2A1-Tom+ cells in the 
lung was assessed. In adoptive transfer experiments (panels B & G) splenocytes were 
obtained from 4T1 mice that had been implanted with 4T1 cells 4 weeks earlier. * indicates 
p< 0.05.
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Figure 3. Neutrophils inhibit NK-mediated clearance of tumor cells
(A) Representative bioluminescent imaging of BALB/c mice injected with D2A1-Tom+ cells 
expressing luciferase. (B) Number of D2A1-Tom+ cells detected in large lobes of lungs at 
the indicated time points after intravenous injection of D2A1-Tom+ cells into control naïve 
mice or 4T1 mice (implanted with 4T1 cells 4 weeks earlier). n ≥ 6 for each time point. (C) 
Number of D2A1-Tom+ cells in lungs of mice 4 hours post i.v. injection of D2A1-Tom+ 
cells. Mice were injected with PBS (control), IgG2A antibody, or anti-asialo-GM-1 antibody 
24 hours before injection of cells. Results show fold increase vs control non-tumor-bearing 
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mice. n ≥ 8 for each group. (D) D2A1-Tom+ lung metastases in mice (fold increase vs. 
control PBS treated mice) following injection of anti-asialo-GM-1 antibody 24 hours after 
injection of cells. n ≥ 5 for each group. (E) Number of D2A1-Tom+ cells detected in lungs 4 
hours after intravenous injection into control non-tumor-bearing mice, 4T1-bearing mice, or 
4T1-bearing mice that had been injected with anti-asialo-GM-1 antibody 24 hours before 
injection of cells. n ≥ 6 for each group. (F) Left: number of YAC-1 cells in lungs of non-
tumor-bearing BALB/c mice 4 hours post intravenous injection of YAC-1 cells. Mice were 
injected with PBS (control), IgG2A antibody, or anti-asialo-GM-1 antibody 24 hours before 
injection of cells. n ≥ 8 for each group. Right: number of YAC-1 cells detected in lungs 4 
hours after intravenous injection into control non-tumor-bearing mice or 4T1-bearing mice. 
n ≥ 6 for each group. (G) YAC-1 cells in lungs (fold increase compared to control mice 
without primary tumors) of 4T1 mice 4 hours post i.v. injection of YAC-1 cells. Mice were 
injected with PBS or anti-Ly6G (1A8) antibody 24 hours before injection of cells. n ≥ 8 for 
each group. (H) Percent of IFN-γ+/CD107a+ NK cells from the spleens (left) and lungs 
(right) of 4T1 tumor-bearing or non-tumor bearing naive mice following in vitro stimulation 
of the cells with NK-activating receptor antibodies or IgG control. n ≥ 6 for each group. In 
panels B,F,G & H, host 4T1 mice had been implanted with 4T1 cells 4 weeks earlier. * 
indicates p< 0.05.
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Figure 4. MMP-8 and MMP-9 facilitate transendothelial migration and metastasis
(A) Intraluminal antibody staining of MDA-MB-231 cells injected i.v. into 4T1-mice 
(implanted with 4T1 cells 4 weeks earlier) or control naïve mice. Graph shows percent of 
MDA-MB-231-Tom+ cells found in the lung that also stained positive by i.v. injected anti-
HLA-2-FITC antibodies. n ≥ 6 for each group. (B) Transendothelial migration of D2A1-
Tom+ cells through HUVECs in the presence of the indicated conditioned media. Results 
present fold increase compared to control RPMI medium. At least 3 experiments were 
performed in duplicates. (C) Representative images of D2A1-Tom+ cells that migrated 
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through HUVECs in the presence of the indicated conditioned media. (D) Transendothelial 
migration of D2A1-Tom+ cells or B16-F10-GFP+ cells through mouse endothelial, bEnd.3, 
cells in the presence of the indicated conditioned media. Results present fold increase 
compared to control RPMI medium. At least 3 experiments were performed in duplicates. 
(E) Transendothelial migration of D2A1 cells (fold increase compared to control RPMI 
medium) through mouse endothelial bEnd.3 cells in the presence of conditioned medium 
from unfractionated splenocytes or the Ly6G+ enriched subpopulation of splenocytes from 
4T1 mice. The number of Ly6G+ cells used to prepare the conditioned medium was 
equivalent to the number of Ly6G+ cells in 1.5 ×107 unfractionated splenocytes population.
(F) Transendothelial migration of D2A1 cells (fold increase compared to control RPMI 
medium) in the presence of conditioned medium from the Ly6G+ enriched subpopulation of 
splenocytes from non-tumor-bearing or 4T1 mice. (G) MMP-8 and MMP-9 secretion by an 
equal number of splenocytes from naïve BALB/c or 4T1–bearing mice. (H) Transendothelial 
migration (fold increase compared to control RPMI) of D2A1cells in the presence of the 
indicated conditioned media, inhibitor or antibody against MMP-8 or antibody against 
MMP-9. At least 3 experiments were performed in duplicates. (I) Immunofluorescent 
staining of MMP-9 (green) and Ly6G (red) in lungs of naïve BALB/c and 4T1 mice 
(implanted with 4T1 cells 4 weeks earlier). Scale bar 25μm. (J) Adoptive transfer of 
splenocytes from WT or MMP-9 KO tumor-bearing mice (implanted with B16-F10-GCSF 
overexpressing cells 3 weeks earlier). Donor splenocytes were injected into WT or MMP9-
KO recipient mice, as indicated. Experiment was terminated 2 weeks later, and pulmonary 
metastases of GFP-labelled B16-F10 cells were quantified. * indicates p< 0.05.
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Figure 5. Neutrophil-secreted IL-1β activates endothelial cells and facilitates migration
(A) Transendothelial migration (fold increase compared to control RPMI medium) of D2A1 
cells following pretreatment of bEnd.3 cells with the indicated conditioned media (prepared 
from equal numbers of splenocytes). The inserts were washed with RPMI medium prior to 
addition of the D2A1 cells. 5 experiments were performed in duplicates. (B) 
Transendothelial migration (fold increase compared to control RPMI medium) of D2A1 
cells following pretreatment of bEnd.3 cells with the indicated conditioned media (prepared 
from equal numbers of splenocytes). The inserts were washed with RPMI medium prior to 
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addition of the D2A1 cells. 5 experiments were performed in duplicates. (C) Secretion of 
MMP-9 by bEnd.3 cells following incubation of the endothelial cells with 4T1-splenocyte-
conditioned medium or splenocyte-conditioned medium from control non-tumor-bearing 
mice (prepared from equal numbers of splenocytes) as determined by ELISA (D) Secretion 
of IL-1β by splenocytes from naïve BALB/c mice, splenocytes from 4T1mice, or Ly6G+ 
neutrophils enriched from splenocytes from 4T1 mice. Levels of IL-1β secreted into the 
conditioned medium were determined by ELISA of at least 5 samples per group. (E) 
Transendothelial migration (fold increase compared to control RPMI) of D2A1 cells 
following pre-incubation of bEnd.3 cells with the indicated conditioned media and in the 
presence of IL-1 β receptor antagonist. At least 4 experiments were performed in duplicates. 
(F) Secretion of MMP-9 by bEnd.3 endothelial cells following incubation of the endothelial 
cells with splenocyte-conditioned medium from control non-tumor-bearing mice, 4T1 tumor 
bearing mice or 4T1 tumor bearing mice together with IL-1 receptor antagonist. MMP-9 
secretion was determined by ELISA of at least 5 samples per treatment. * indicates p< 0.05.
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Figure 6. Visualization of protrusion and extravasation dynamics of tumor cells
(A) Left - high resolution time-lapse confocal microscopy (20X) of an extravasating MDA-
MB-231 cell (red) immediately after seeding in microvasculature network (HUVEC cells 
labeled in green). Right - confocal images taken at a single slice tracking a tumor cells as it 
transmigrates through the endothelium and into the 3D matrix over a period of 3 hours. (B) 
Protrusion formation (red) and extravasation (blue) rates of MDA-MB-231 cells in HUVEC 
vessels that had been pre-treated with 4T1 splenocyte conditioned medium or Control 
(RPMI). (C) Time required for protrusion formation (i.e. partial translocation across the 
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lumen) and (D) time required for complete extravasation (i.e. the entire cell body has cleared 
the lumen) of MDA-MB-231 cells in HUVEC vessels that had been pre-treated with 4T1 
splenocyte conditioned medium or Control (RPMI). Data were collected from >150 cells per 
condition, over 3 independent experiments. (E) Events leading to metastasis of circulating 
tumor cells: 1) Primary tumor perturbs distant organs, leading to neutrophil expansion and 
mobilization. 2) Neutrophils increase intraluminal survival of circulating tumor cells by 
inhibiting their clearance by NK cells. 3) Neutrophils increase extravasation of circulating 
tumor cells through secretion of IL-1β and MMPs. * indicates p< 0.05.
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